| Market News | | |
| |
| 1 (-6) $49 Wegovy Copycat Pill Sparks Selloff In Novo Shares ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero (https://www.zerohedge.com/) Thu. Feb 5, 2026 |
| 2 (-5) Hims & Hers launch of compounded $49 Wegovy pill pummels Novo Nordisk’s shares The compounded pill is less expensive than the oral version of Wegovy, which costs $149 to get started. (https://www.marketwatch.com/) Thu. Feb 5, 2026 |
| 3 (-4) Novo’s Victory Lap for Weight-Loss Pill Spoiled by Hims’ Copycat Not even two days after Novo Nordisk A/S touted its weight-loss pill as one of the most successful drug launches ever, a knock-off version is already on the market. (https://www.bloomberg.com/) Thu. Feb 5, 2026 |
| 4 (-6) Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill Novo Nordisk and Eli Lilly fell after Hims & Hers said it will offer a copy of the Wegovy pill for $49, far less than the $149 Novo sells the branded pill for. (https://www.cnbc.com/) Thu. Feb 5, 2026 |
| 5 (-6) Hims & Hers launch of compounded $49 Wegovy pill pummels Novo Nordisk’s shares The compounded pill is less expensive than the oral version of Wegovy, which costs $149 to get started. (https://www.marketwatch.com/) Thu. Feb 5, 2026 |
| |
| 6 (-7) Novo Slump Is No Buy-the-Dip Moment for Top Danish Investor Denmark’s largest pension fund sees no buy-the-dip opportunity in Novo Nordisk A/S’s shares after the drugmaker warned that sales will fall in 2026, underscoring how investors on its home turf have little confidence in the stock. (https://www.bloomberg.com/) Thu. Feb 5, 2026 |
| 7 (-6) Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up Recently-appointed CEO Mike Doustdar has repeatedly reset expectations since his arrival. Pricing and regulatory pressure is fierce and pessimistic revenue guidance has seen the stock clobbered 17% in Copenhagen. (https://www.marketwatch.com/) Wed. Feb 4, 2026 |
| 8 (8) Novo to launch Ozempic pill for diabetes in second quarter of this year Feb 4 () - Novo Nordisk said on Wednesday it will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year. Food and Drug Administration has approved Ozempic tablets in 1. (https://finance.yahoo.com/) Wed. Feb 4, 2026 |
| 9 (-5) Novo CEO Asks Investors to Trust Him With Sales Set to Fall Novo Nordisk A/S’s chief executive officer is asking investors to trust him that a surge in new prescriptions as obesity drugs get cheaper will eventually revive sales growth. The plunge in the company’s shares shows they aren’t yet convinced. (https://www.bloomberg.com/) Wed. Feb 4, 2026 |
| 10 (2) CNBC Daily Open: UBS posts strong earnings while Novo Nordisk's U.S. shares crater on slowing growth Nvidia CEO Jensen Huang told CNBC's Jim Cramer on Tuesday that there's "no drama involved" between the company and OpenAI. "Everything's on track," he added. (https://www.cnbc.com/) Wed. Feb 4, 2026 |
| |
| 11 (-7) Novo Nordisk shares tumble 18% as CEO warns it will get worse before it gets better Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its 2026 forecast late Tuesday, sending shares tumbling. (https://www.cnbc.com/) Wed. Feb 4, 2026 |
| 12 (-6) Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up Recently-appointed CEO Mike Doustdar has repeatedly reset expectations since his arrival. Pricing and regulatory pressure is fierce and pessimistic revenue guidance has seen the stock clobbered 17% in Copenhagen. (https://www.marketwatch.com/) Wed. Feb 4, 2026 |